// App-Quantinova.ai

4633 : The DNA strand breaking nucleoside analogue sapacitabine sensitizes Brca2-deficient ovarian cancer cells and synergizes with PARP inhibitors

Researchers

Presenter

  • Xiaojun Liu

Principal Investigators

  • Yingjun Jiang

  • Billie Nowak

  • Bethany Qiang

  • Nancy Cheng

  • William Plunkett

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gynaecological cancer

  • Acute Leukemia

  • Solid malignancies

Biomarkers

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Decitabine

  • sapacitabine

  • Gemcitabine

  • Oxaliplatin

  • Talazoparib

  • Cytarabine liposomal

  • Paclitaxel

  • Rucaparib

  • DFP 10917

  • Docetaxel

  • Cisplatin

  • taxane

  • CNDAC

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved